Due diligence of a generic inhaler platform
Team Consulting carried out a highly confidential due diligence and technical audit of a generic inhaler platform. The aim was to support a client’s decision on whether to procure both the technology and the company.
We performed a detailed review of the target company’s technical file documentation, to ensure due process had been followed and appropriately implemented. Drawing on our team’s medical device expertise, we also reviewed the device design itself, to assess performance, robustness and readiness for high volume manufacture. This analysis was then used to determine suitability for submission via the 505(j) regulatory pathway. Finally, we assessed the target company’s overall capabilities, quality systems and tools.
We presented a detailed summary report to our client, to support them in making a multi-million pound decision on a company buyout.